HTA ID Drug Brand Indication Assessment status Date
- Trientine Tetrahydrochloride (TETA 4HCL) Cuprior® For the treatment of Wilson’s disease in adults and children ≥ five years intolerant to D-penicillamine therapy. Rapid Review Complete 9th October 2019
- Trifluridine/tipiracil Lonsurf® For the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents. Rapid Review Complete 13th July 2016
22011 Trifluridine/tipiracil Lonsurf® As monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease. Rapid Review Complete 15th March 2022
22058 Tucatinib Tukysa® In combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer wo have received at least two prior anti-HER2 treatment regimens. NCPE assessment ongoing 18th August 2025